Ramucirumab

Ramucirumab Reactions 1680, p294 - 2 Dec 2017 Wound healing failure: case report A 51-year-old man developed wound healing failure following the therapy with ramucirumab. The man had metastatic stage IV lung adenocarcinoma. He had received carboplatin, pemetrexed and bevacizumab. However, due to disease progression, his medication was altered to docetaxel and ramucirumab 10 mg/kg [route not stated]. After two weeks of cycle 1, he underwent right jugular port placement for the adenocarcinoma. Six days later, he received another cycle of docetaxel and ramucirumab using a peripheral access, since the chest wall site was noted not to have healed. A third cycle of docetaxel and ramucirumab was administered peripherally after one month of the port placement. The chest incision site was noted to be tender with incomplete healing. One week later, the port site and venotomy incisions were not well apposed, with mild exudate from the incision. It was then revealed that the wound healing failure was due to the ramucirumab therapy. The man’s ramucirumab therapy was discontinued. He then received treatment with cefalexin. After one month, there was slight improvement in the port reservoir site, but the venotomy site was open and had not improved. The port was then removed and then a new port placed on the left side. Author comment: "In this case, the poor wound healing likely represents an adverse effect of ramucirumab". Zhan C, et al. Wound Healing Failure Following Venous Access Chest Port Placement Associated with Ramucirumab Therapy. Cardiovascular and Interventional Radiology 40: 1804-1806, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1007/s00270-017-1752-8 - USA 803285097 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ramucirumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/ramucirumab-DE2qdnD7KQ
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39225-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p294 - 2 Dec 2017 Wound healing failure: case report A 51-year-old man developed wound healing failure following the therapy with ramucirumab. The man had metastatic stage IV lung adenocarcinoma. He had received carboplatin, pemetrexed and bevacizumab. However, due to disease progression, his medication was altered to docetaxel and ramucirumab 10 mg/kg [route not stated]. After two weeks of cycle 1, he underwent right jugular port placement for the adenocarcinoma. Six days later, he received another cycle of docetaxel and ramucirumab using a peripheral access, since the chest wall site was noted not to have healed. A third cycle of docetaxel and ramucirumab was administered peripherally after one month of the port placement. The chest incision site was noted to be tender with incomplete healing. One week later, the port site and venotomy incisions were not well apposed, with mild exudate from the incision. It was then revealed that the wound healing failure was due to the ramucirumab therapy. The man’s ramucirumab therapy was discontinued. He then received treatment with cefalexin. After one month, there was slight improvement in the port reservoir site, but the venotomy site was open and had not improved. The port was then removed and then a new port placed on the left side. Author comment: "In this case, the poor wound healing likely represents an adverse effect of ramucirumab". Zhan C, et al. Wound Healing Failure Following Venous Access Chest Port Placement Associated with Ramucirumab Therapy. Cardiovascular and Interventional Radiology 40: 1804-1806, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1007/s00270-017-1752-8 - USA 803285097 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off